Project Grant R01CA291771
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$484K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Sacramento, CA 95817, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) provides $468,139 to Tulane University to investigate the role of the long non-coding RNA CRNDE in suppressing anti-tumor immune responses in hepatocellular carcinoma (HCC). The key objectives are to: Elucidate the molecular mechanisms by which HCC-derived CRNDE inhibits the anti-tumor immune function of tumor-infiltrating lymphocytes (TILs) and promotes HCC tumor growth. This will involve...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Rutgers, The State University of New Jersey will support a $1,352,991 research project over 5 years starting on July 1, 2024. The research aims to study the role of urea cycle enzymes (UCEs) in the growth and development of hepatocellular carcinoma (HCC), the primary type of liver cancer. Specifically, the project will: 1) test if suppression of UCE expression contributes to HCC...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of Columbia University in the City of New York, with a total funding of $687,679. The grant will fund research aimed at understanding and targeting transcriptional master regulators in hepatocellular carcinoma (HCC). The project seeks to computationally establish HCC transcriptional master regulators, validate their tumor cell-intrinsic functions...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme for the treatment of hepatocellular carcinoma (HCC). The key objectives are to: 1) identify CYP8B1 inhibitors through high-throughput screening, 2) validate the hits for potency, specificity, and structure-activity relationships, and 3) determine...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $536,836 to The University of Texas MD Anderson Cancer Center to develop mathematical models and computational methodologies to optimize the delivery of a transarterial ablative therapy for treating hepatocellular carcinoma. The key objectives are to: Formulate mathematical models that capture the complex multiphase flow, heat transfer, and chemical reactions occurring...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $678,515 to The University of Texas MD Anderson Cancer Center to evaluate 18F-FSPG PET imaging and circulating tumor DNA (ctDNA) as innovative approaches to predict response and recurrence for patients with hepatocellular carcinoma (liver cancer) undergoing yttrium-90 radioembolization therapy. The project aims to determine if 18F-FSPG PET can predict response to therapy...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a performance period from March 1, 2025 to February 28, 2027, will support research to metabolically reprogram hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven hepatocellular carcinoma. The project aims to determine how TSC1-deficient hepatic macrophages can...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $599,299 to the University of Illinois to study the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and the development of hepatocellular carcinoma (HCC) from non-alcoholic steatohepatitis (NASH). The research aims to validate the importance of HK2 in driving liver fibrosis and its effects on NASH-induced HCC. The project will employ mouse models to investigate how...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $300,000 to the University of California, Davis to conduct research on the epidemiology of the gut-liver axis and hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The goal is to identify novel bacteria, metabolites, and glycoproteins associated with HCC risk, particularly in the Latinx population who are underrepresented in current...